Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01441947 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT01441947: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT01441947 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 68 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01441947, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
The study drug cabozantinib works by inhibiting several different proteins which are believed to be involved in breast cancer tumor growth, its ability to spread, and its ability to form new blood vessels. This drug has been used in other research studies and information from those other research studies suggests that this drug may help to prevent cancer growth. The single agent portion of this study is now closed to accrual. This research study is now examining the efficacy of cabozantinib in combination with fulvestrant for treatment of hormone-receptor-positive breast cancer that has spread to bone.
Interventions
- DRUG Fulvestrant
- DRUG Cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2011-10 |
| Est. Completion | 2019-08-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01441947
The ClinicalTrials.gov registry entry for NCT01441947 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fulvestrant is the first listed.
NCT01441947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01441947 about?
NCT01441947 is a clinical study titled "Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer". The study drug cabozantinib works by inhibiting several different proteins which are believed to be involved in breast cancer tumor growth, its ability to spread, and its ability to form new blood vessels. This drug has been used in other research studies and information from those other research st...
What is the current status of trial NCT01441947?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2011-10. Estimated completion is 2019-08-09.
What interventions are being tested in trial NCT01441947?
The interventions under investigation include: Fulvestrant (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT01441947?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.